Pamidronic acid

Revision as of 19:28, 27 September 2011 by WikiBot (talk | contribs) (Protected "Pamidronic acid": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
Jump to navigation Jump to search
Pamidronic acid
Clinical data
Pregnancy
category
  • AU: B3
  • US: D (Evidence of risk)
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailabilityn/a
Protein binding54%
MetabolismNil
Elimination half-life28 ± 7 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC3H11NO7P2
Molar mass235.07 g/mol

WikiDoc Resources for Pamidronic acid

Articles

Most recent articles on Pamidronic acid

Most cited articles on Pamidronic acid

Review articles on Pamidronic acid

Articles on Pamidronic acid in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pamidronic acid

Images of Pamidronic acid

Photos of Pamidronic acid

Podcasts & MP3s on Pamidronic acid

Videos on Pamidronic acid

Evidence Based Medicine

Cochrane Collaboration on Pamidronic acid

Bandolier on Pamidronic acid

TRIP on Pamidronic acid

Clinical Trials

Ongoing Trials on Pamidronic acid at Clinical Trials.gov

Trial results on Pamidronic acid

Clinical Trials on Pamidronic acid at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pamidronic acid

NICE Guidance on Pamidronic acid

NHS PRODIGY Guidance

FDA on Pamidronic acid

CDC on Pamidronic acid

Books

Books on Pamidronic acid

News

Pamidronic acid in the news

Be alerted to news on Pamidronic acid

News trends on Pamidronic acid

Commentary

Blogs on Pamidronic acid

Definitions

Definitions of Pamidronic acid

Patient Resources / Community

Patient resources on Pamidronic acid

Discussion groups on Pamidronic acid

Patient Handouts on Pamidronic acid

Directions to Hospitals Treating Pamidronic acid

Risk calculators and risk factors for Pamidronic acid

Healthcare Provider Resources

Symptoms of Pamidronic acid

Causes & Risk Factors for Pamidronic acid

Diagnostic studies for Pamidronic acid

Treatment of Pamidronic acid

Continuing Medical Education (CME)

CME Programs on Pamidronic acid

International

Pamidronic acid en Espanol

Pamidronic acid en Francais

Business

Pamidronic acid in the Marketplace

Patents on Pamidronic acid

Experimental / Informatics

List of terms related to Pamidronic acid

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia®, is a bisphosphonate.

Uses

It is used to prevent bone loss, and treat osteoporosis. It is also used to strengthen bone in Paget's disease, to prevent bone loss due to steroid use, and in certain cancers with high propensity to bone, such as multiple myeloma. In multiple myeloma, it is usually administered as an intravenous infusion, lasting about 3 hours. The therapy is repeated monthly, and lasts for the life of the patient. Due to its ability to sequester calcium in bone, it is also used to treat high calcium levels.

Administration

Intravenous, usually 90 mg monthly. 30 mg, 60 mg, and 90 mg vials are available, mixed with mannitol.

Side effects

Common side effects include bone pain, low calcium levels, nausea, and dizziness. Osteonecrosis of the jaw is a rare complication which has been associated with the use of bisphosphonates, including pamidronate.[1]

Pamidronate activates human γδ T cells in vitro and in vivo, which may lead to flu-like symptoms upon administration.

References

  1. Zarychanski R, Elphee E, Walton P, Johnston J (2006). "Osteonecrosis of the jaw associated with pamidronate therapy". Am J Hematol. 81 (1): 73–5. PMID 16369966.

Template:SIB Template:Bisphosphonates


Template:WikiDoc Sources